Literature DB >> 29320654

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Michael A Postow1, Robert Sidlow1, Matthew D Hellmann1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29320654     DOI： 10.1056/NEJMra1703481

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1006 in total

1.  Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Authors:  James Randall Patrinely; Arissa C Young; Henry Quach; Grant R Williams; Fei Ye; Run Fan; Leora Horn; Kathryn E Beckermann; Erin A Gillaspie; Jeffrey A Sosman; Debra L Friedman; Javid J Moslehi; Douglas B Johnson
Journal:  Eur J Cancer       Date:  2020-06-27       Impact factor: 9.162

2.  Neurotoxicities associated with immune checkpoint inhibitor therapy.

Authors:  Sophie L Duong; Frank J Barbiero; Richard J Nowak; Joachim M Baehring
Journal:  J Neurooncol       Date:  2021-01-17       Impact factor: 4.130

Review 3.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

4.  Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Authors:  Henry T Quach; Charles J Robbins; Justin M Balko; Charles Y Chiu; Steve Miller; Michael R Wilson; George E Nelson; Douglas B Johnson
Journal:  Oncologist       Date:  2019-04-01

Review 5.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

Review 6.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

7.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 8.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151

9.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

10.  Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Authors:  Heinz Läubli; Stefan Dirnhofer; Alfred Zippelius
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.